WO2001030323A3 - Controlled-release biocompatible ocular drug delivery implant devices and methods - Google Patents

Controlled-release biocompatible ocular drug delivery implant devices and methods Download PDF

Info

Publication number
WO2001030323A3
WO2001030323A3 PCT/US2000/029004 US0029004W WO0130323A3 WO 2001030323 A3 WO2001030323 A3 WO 2001030323A3 US 0029004 W US0029004 W US 0029004W WO 0130323 A3 WO0130323 A3 WO 0130323A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
devices
drug delivery
controlled
release
Prior art date
Application number
PCT/US2000/029004
Other languages
French (fr)
Other versions
WO2001030323A2 (en
Inventor
Vernon G Wong
Mae W L Hu
Donald E Berger Jr
Original Assignee
Oculex Pharm Inc
Vernon G Wong
Mae W L Hu
Donald E Berger Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oculex Pharm Inc, Vernon G Wong, Mae W L Hu, Donald E Berger Jr filed Critical Oculex Pharm Inc
Priority to BR0007454-3A priority Critical patent/BR0007454A/en
Priority to CA002355313A priority patent/CA2355313C/en
Priority to EA200100694A priority patent/EA200100694A1/en
Priority to AU12187/01A priority patent/AU1218701A/en
Priority to KR1020017007940A priority patent/KR20010099888A/en
Priority to EP00973704A priority patent/EP1143935A3/en
Priority to JP2001532743A priority patent/JP4070460B2/en
Publication of WO2001030323A2 publication Critical patent/WO2001030323A2/en
Priority to NO20013094A priority patent/NO20013094L/en
Publication of WO2001030323A3 publication Critical patent/WO2001030323A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Abstract

Controlled release devices are disclosed which are biocompatible and can be implanted into the eye. The devices have a core comprising a drug and a polymeric outer layer which is substantially impermeable to the entrance of an environmental fluid and substantially impermeable to the release of the drug during a delivery period, and drug release is affected through an orifice in the outer layer. These devices have an orifice area of less than 10 % of the total surface area of the device and can be used to deliver a variety of drugs with varying degrees of solubility and or molecular weight. Methods are also provided for using these drug delivery devices.
PCT/US2000/029004 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods WO2001030323A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BR0007454-3A BR0007454A (en) 1999-10-22 2000-10-19 Implant devices and methods with biocompatible drug transfer controlled deliberation in the ocular system
CA002355313A CA2355313C (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods
EA200100694A EA200100694A1 (en) 1999-10-22 2000-10-19 BIOS COMPATIBLE IMPLANTABLE MEANS OF DELIVERY OF THE EYE DRUG WITH CONTROLLED DELIVERY AND METHODS OF THEIR APPLICATION
AU12187/01A AU1218701A (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods
KR1020017007940A KR20010099888A (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods
EP00973704A EP1143935A3 (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods
JP2001532743A JP4070460B2 (en) 1999-10-22 2000-10-19 Controlled release biocompatible ophthalmic drug delivery implant device and method
NO20013094A NO20013094L (en) 1999-10-22 2001-06-21 Biocompatible, ocular, drug-releasing implant devices with controlled release action, and methods of action

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/426,141 US6331313B1 (en) 1999-10-22 1999-10-22 Controlled-release biocompatible ocular drug delivery implant devices and methods
US09/426,141 1999-10-22

Publications (2)

Publication Number Publication Date
WO2001030323A2 WO2001030323A2 (en) 2001-05-03
WO2001030323A3 true WO2001030323A3 (en) 2002-02-21

Family

ID=23689481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029004 WO2001030323A2 (en) 1999-10-22 2000-10-19 Controlled-release biocompatible ocular drug delivery implant devices and methods

Country Status (11)

Country Link
US (1) US6331313B1 (en)
EP (1) EP1143935A3 (en)
JP (1) JP4070460B2 (en)
KR (1) KR20010099888A (en)
CN (1) CN1360497A (en)
AU (1) AU1218701A (en)
BR (1) BR0007454A (en)
CA (1) CA2355313C (en)
EA (1) EA200100694A1 (en)
NO (1) NO20013094L (en)
WO (1) WO2001030323A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968766B2 (en) 2004-04-30 2015-03-03 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8999397B2 (en) 2004-04-30 2015-04-07 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9233070B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants

Families Citing this family (432)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
CA2320259C (en) 1998-04-27 2006-01-24 Surmodics, Inc. Bioactive agent release coating
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
DE60037406T2 (en) 1999-04-26 2008-05-21 GMP Vision Solutions, Inc., Ft. Lauderdale INFLATABLE DEVICE FOR TREATING GLAUCOMA
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7682647B2 (en) 1999-09-03 2010-03-23 Advanced Cardiovascular Systems, Inc. Thermal treatment of a drug eluting implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6908624B2 (en) * 1999-12-23 2005-06-21 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US6638239B1 (en) 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US20040208910A1 (en) * 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20040175410A1 (en) * 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US7682648B1 (en) 2000-05-31 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for forming polymeric coatings on stents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE60135352D1 (en) * 2000-08-30 2008-09-25 Univ Johns Hopkins DEVICE FOR INTRA-OCCULAR ACTIVE AGGREGATION
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US7807210B1 (en) 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6824559B2 (en) 2000-12-22 2004-11-30 Advanced Cardiovascular Systems, Inc. Ethylene-carboxyl copolymers as drug delivery matrices
WO2002058667A2 (en) * 2001-01-26 2002-08-01 Bausch & Lomb Incorporated Improved process for the production of sustained release drug delivery devices
US20020148138A1 (en) * 2001-04-06 2002-10-17 Egan Brian A. Smart tread boot covers
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7488303B1 (en) 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
ES2304438T3 (en) 2001-04-07 2008-10-16 Glaukos Corporation GLAUCOMA STENT FOR THE TREATMENT OF GLAUCOMA.
US6712845B2 (en) 2001-04-24 2004-03-30 Advanced Cardiovascular Systems, Inc. Coating for a stent and a method of forming the same
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
AU2002305400A1 (en) 2001-05-03 2002-11-18 Glaukos Corporation Medical device and methods of use for glaucoma treatment
US6656506B1 (en) 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
DE60239868D1 (en) 2001-06-12 2011-06-09 Univ Johns Hopkins Med RESERVOIR DEVICE FOR INTRAOCULAR DRUG DELIVERY
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6695920B1 (en) 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US7682669B1 (en) 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
JP2005502426A (en) 2001-09-14 2005-01-27 フランシス ジェイ マーティン Microfabricated nanopore devices for sustained release of therapeutic agents
US7989018B2 (en) 2001-09-17 2011-08-02 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
CN1638743B (en) * 2002-03-11 2012-11-07 爱尔康公司 Implantable drug delivery system
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US7919075B1 (en) 2002-03-20 2011-04-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
WO2003087367A2 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
MXPA04011416A (en) 2002-05-17 2005-09-30 Othera Pharmaceuticals Inc Amelioration of the development of cataracts and other opthalmic diseases.
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US6930127B2 (en) * 2002-08-15 2005-08-16 Eaton Veterinary Laboratories, Inc. Veterinary treatment of ophthalmic disease in animals using topical tacrolimus
US7087263B2 (en) 2002-10-09 2006-08-08 Advanced Cardiovascular Systems, Inc. Rare limiting barriers for implantable medical devices
WO2004036182A2 (en) * 2002-10-17 2004-04-29 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7022372B1 (en) 2002-11-12 2006-04-04 Advanced Cardiovascular Systems, Inc. Compositions for coating implantable medical devices
US20050013845A1 (en) * 2002-11-12 2005-01-20 Warren Stephen L. Adhesive bioerodible ocular drug delivery system
US7776926B1 (en) 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7074276B1 (en) 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US8435550B2 (en) 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US20060002968A1 (en) 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US7758881B2 (en) 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US8185209B2 (en) * 2003-01-03 2012-05-22 Board Of Trustees Operating Michigan State University Methods to extend vision to infrared wavelengths
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
EP1604010B1 (en) 2003-01-16 2010-08-11 The Trustees of The University of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1
US7037521B2 (en) * 2003-03-28 2006-05-02 Bausch & Lomb Incorporated Using a laser for cutting a hole in a capsule for controlled drug delivery
US7012106B2 (en) * 2003-03-28 2006-03-14 Ethicon, Inc. Reinforced implantable medical devices
US7572298B2 (en) * 2003-03-28 2009-08-11 Ethicon, Inc. Implantable medical devices and methods for making same
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
EP1633320A2 (en) 2003-05-02 2006-03-15 SurModics, Inc. Implantable controlled release bioactive agent delivery device
US20040225250A1 (en) 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US7413734B2 (en) 2003-06-27 2008-08-19 Ethicon, Incorporated Treatment of retinitis pigmentosa with human umbilical cord cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US20050054586A1 (en) * 2003-06-30 2005-03-10 Bartels Stephen P. Treatment of ophthalmic disorders
US20040265356A1 (en) * 2003-06-30 2004-12-30 Bausch & Lomb Incorporated Drug delivery device
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7056591B1 (en) 2003-07-30 2006-06-06 Advanced Cardiovascular Systems, Inc. Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7645474B1 (en) 2003-07-31 2010-01-12 Advanced Cardiovascular Systems, Inc. Method and system of purifying polymers for use with implantable medical devices
US7431959B1 (en) 2003-07-31 2008-10-07 Advanced Cardiovascular Systems Inc. Method and system for irradiation of a drug eluting implantable medical device
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) * 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
EP1677664B1 (en) * 2003-09-23 2014-07-30 Orthocon Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
AU2004279320A1 (en) 2003-09-23 2005-04-21 Ortho Therapeutics, Llc. Bioabsorbable putty-like hemostatic implants
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US7441513B1 (en) 2003-09-26 2008-10-28 Advanced Cardiovascular Systems, Inc. Plasma-generated coating apparatus for medical devices and a method of coating deposition
US8016865B2 (en) * 2003-09-29 2011-09-13 Depuy Mitek, Inc. Method of performing anterior cruciate ligament reconstruction using biodegradable interference screw
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US7318932B2 (en) 2003-09-30 2008-01-15 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices comprising hydrolitically stable adducts of poly(ethylene-co-vinyl alcohol) and methods for fabricating the same
US7704544B2 (en) 2003-10-07 2010-04-27 Advanced Cardiovascular Systems, Inc. System and method for coating a tubular implantable medical device
US7329413B1 (en) 2003-11-06 2008-02-12 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7291125B2 (en) 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
ZA200604403B (en) * 2003-11-20 2007-09-26 Othera Pharmaceuticals Inc Amelioration of macular degeneration and other ophthalmic diseases
US8192752B2 (en) 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
US7560492B1 (en) 2003-11-25 2009-07-14 Advanced Cardiovascular Systems, Inc. Polysulfone block copolymers as drug-eluting coating material
US7807722B2 (en) 2003-11-26 2010-10-05 Advanced Cardiovascular Systems, Inc. Biobeneficial coating compositions and methods of making and using thereof
WO2005057272A2 (en) * 2003-12-05 2005-06-23 Innfocus, Llc Improved ocular lens
JP5090742B2 (en) * 2003-12-05 2012-12-05 インフォーカス リミテッド ライアビリティー カンパニー Improved glaucoma transplant device
US7435788B2 (en) 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US8309112B2 (en) 2003-12-24 2012-11-13 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
US20070053963A1 (en) * 2004-01-13 2007-03-08 Hotchkiss Robert N Drug delivery to a joint
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005070011A2 (en) 2004-01-23 2005-08-04 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US8685431B2 (en) 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8551512B2 (en) 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
WO2006033020A2 (en) * 2004-04-26 2006-03-30 Rosetta Genomics Ltd. Methods and apparatus for the detection and validation of micrornas
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8293890B2 (en) 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7820732B2 (en) 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
AU2011213904B2 (en) * 2004-04-30 2014-06-05 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
JP2008500359A (en) * 2004-05-25 2008-01-10 オセラ・フアーマシユーチカルズ・インコーポレーテツド Ocularselective drugs and prodrugs
US9561309B2 (en) 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
CA2572592C (en) 2004-07-02 2015-09-08 Eliot Lazar Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
WO2006014484A2 (en) 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
JP2008505978A (en) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド Ophthalmic composition and eye disease treatment method
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
ES2432556T3 (en) 2004-08-04 2013-12-04 Evonik Corporation Methods for manufacturing supply devices and their devices
US7648727B2 (en) 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7244443B2 (en) 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US8603528B2 (en) * 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
US8110211B2 (en) 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US20060067979A1 (en) * 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
JP5682991B2 (en) 2004-10-01 2015-03-11 ラムズコア， インコーポレイテッド Convenient implantable sustained release drug formulation
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8043609B2 (en) 2004-10-08 2011-10-25 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US8246949B2 (en) * 2004-10-27 2012-08-21 Aciont, Inc. Methods and devices for sustained in-vivo release of an active agent
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US7390497B2 (en) 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7547447B2 (en) * 2004-11-15 2009-06-16 Doheny Eye Institute Bioartificial lacrimal gland
CN101102779A (en) * 2004-11-17 2008-01-09 乔安妮·麦克劳林 Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
US7214759B2 (en) * 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
JP2008521489A (en) * 2004-11-24 2008-06-26 テラカイン コーポレイション Implants for intraocular drug delivery
US8609123B2 (en) 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US7604818B2 (en) 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
AU2005322068B2 (en) 2004-12-23 2011-09-01 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
PL1831356T3 (en) * 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US7419504B2 (en) 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2564194T3 (en) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Liquid formulations for the treatment of diseases or ailments
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US20070077270A1 (en) * 2005-03-28 2007-04-05 Clemson University Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
WO2006127592A2 (en) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
US7823533B2 (en) 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7749530B2 (en) * 2005-07-13 2010-07-06 Allergan, Inc. Kinase inhibitors
EP1907006A2 (en) * 2005-07-15 2008-04-09 Chakshu Research, Inc. Prevention and treatment of ophthalmic complications of diabetes
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US7785647B2 (en) 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
KR20080055782A (en) * 2005-07-25 2008-06-19 오소콘 인코퍼레이티드 Compositions and methods for the reduction of post-operative pain
CA2616537A1 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
WO2007037849A2 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007119108A2 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
KR101430760B1 (en) * 2005-10-18 2014-08-19 알러간, 인코포레이티드 Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
AU2006320535B2 (en) 2005-11-29 2010-09-23 Glaxosmithkline Llc Treatment method
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
WO2007073552A1 (en) 2005-12-19 2007-06-28 Ethicon, Inc. In vitro expansion of postpartum derived cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
ES2747956T3 (en) * 2005-12-30 2020-03-12 Rdd Pharma Ltd Device to treat anal sphincter
CA2637602C (en) 2006-01-17 2014-09-16 Forsight Labs, Llc Drug delivery treatment device
EP3005996B1 (en) 2006-01-17 2019-12-04 Novartis Ag Glaucoma treatment device
ES2385924T3 (en) 2006-02-02 2012-08-03 Allergan, Inc. CXCR4 activity inhibitors for use in the treatment of eye disorders
KR20140093764A (en) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 Stable formulations, and methods of their preparation and use
EP1991210A1 (en) * 2006-02-15 2008-11-19 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US20070196428A1 (en) 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
WO2007129221A2 (en) * 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US7713637B2 (en) 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
MX2008011553A (en) * 2006-03-09 2008-12-09 Waratah Pharmaceuticals Inc A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation.
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
EP3449873A1 (en) * 2006-03-31 2019-03-06 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US8304012B2 (en) 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
CA2652449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
US7775178B2 (en) 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US9561351B2 (en) 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8568764B2 (en) 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
EP2383341A1 (en) 2006-06-12 2011-11-02 Exegenics, Inc., D/b/a Opko Health, Inc. Compositions and methods for siRNA inhibition of angiogenesis
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
PL2044111T3 (en) 2006-06-21 2015-02-27 Musc Found For Res Dev Targeting complement factor h for treatment of diseases
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9028859B2 (en) 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US8586556B2 (en) 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
CA2668954C (en) 2006-11-10 2020-09-08 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US8143410B2 (en) 2006-11-16 2012-03-27 Allergan, Inc. Kinase inhibitors
US20100292157A1 (en) * 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2091482A2 (en) 2006-12-01 2009-08-26 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8597673B2 (en) 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
GB0713463D0 (en) 2007-07-11 2007-08-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
AU2008214359B2 (en) 2007-02-05 2014-01-16 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
CN101687786B (en) 2007-02-22 2013-05-22 奥特拉控股公司 Hydroxylamine compounds and methods of their use
PT2148667E (en) 2007-04-12 2013-08-28 Waratah Pharmaceuticals Inc Use of cyclohexanehexol derivatives in the treatment of ocular diseases
CA2683548A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
WO2008124929A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
US8147769B1 (en) 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
WO2009003226A1 (en) * 2007-06-29 2009-01-08 Clarencew Pty Ltd Treatment or prophylaxis or neurological or neuropsychiatric disorders via ocular administration
EP2173289A4 (en) 2007-07-17 2010-11-24 Transcend Medical Inc Ocular implant with hydrogel expansion capabilities
MX2010002616A (en) 2007-09-07 2010-08-04 Qlt Plug Delivery Inc Drug cores for sustained release of therapeutic agents.
ES2732555T3 (en) 2007-09-07 2019-11-25 Mati Therapeutics Inc Tear implants and related methods
EP2205193A2 (en) 2007-09-07 2010-07-14 QLT Plug Delivery, Inc. Lacrimal implant detection
UA99152C2 (en) 2007-10-05 2012-07-25 Этикон, Инкорпорейтед Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
EP2209888B1 (en) 2007-10-12 2019-12-04 Astellas Institute for Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
RU2010128543A (en) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) CARBOXAMIDE COMPOUNDS AND THEIR APPLICATION AS AN CHEMOKIN RECEPTOR AGONISTS
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
CN102014816B (en) 2008-02-18 2015-04-15 马缇医疗股份有限公司 Lacrimal implants and related methods
JP5552482B2 (en) 2008-04-30 2014-07-16 キュー エル ティー インク． Composite lacrimal insert and related methods
BRPI0912182A2 (en) 2008-05-09 2015-10-06 Qlt Plug Delivery Inc prolonged release distribution of active agents to treat glaucoma and ocular hypertension
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2276439A4 (en) 2008-05-12 2013-11-27 Univ Utah Res Found Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US8617139B2 (en) 2008-06-25 2013-12-31 Transcend Medical, Inc. Ocular implant with shape change capabilities
CA2753338A1 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters
CN101390825B (en) * 2008-10-01 2010-12-29 山东省眼科研究所 Intra-ocular release system of voriconazole
AU2009301603A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US20100121441A1 (en) * 2008-11-10 2010-05-13 Nabil Jabbour Surgical implant and method
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
AU2009322279A1 (en) 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US8377122B2 (en) 2009-01-28 2013-02-19 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
WO2010088548A1 (en) 2009-01-29 2010-08-05 Forsight Labs, Llc Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010096822A2 (en) 2009-02-23 2010-08-26 Qlt Plug Delivery, Inc. Lacrimal implants and related methods
US20100226962A1 (en) * 2009-03-03 2010-09-09 Rodstrom Theron R Peri-corneal drug delivery device
BRPI1013409A2 (en) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc human umbilical cord tissue cells as therapy for alzheimer's disease
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102655823B (en) * 2009-05-18 2016-04-20 多斯医学公司 Medicament elution ocular implant
IN2012DN00352A (en) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
EP2445481B1 (en) * 2009-06-18 2017-03-22 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
EP2493459B1 (en) * 2009-10-30 2016-08-24 Aton Pharma, Inc. Ocular drug delivery devices
PL2498783T3 (en) 2009-11-09 2019-04-30 Allergan Inc Compositions and methods for stimulating hair growth
KR102073730B1 (en) 2009-11-17 2020-02-05 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
WO2011069155A1 (en) * 2009-12-04 2011-06-09 Opko Ophthalmics, Llc Compositions and methods for inhibition of vegf
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
CN106074591B (en) 2010-03-24 2020-01-14 菲奥医药公司 RNA interference in ocular symptoms
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
BR112012033119A2 (en) 2010-06-22 2016-10-25 Univ Colorado Regents antibodies to complement component c3d fragment 3.
AU2011270754B2 (en) 2010-06-25 2015-04-23 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Methods of treatment using sterculic acid
HUE054517T2 (en) 2010-07-23 2021-09-28 Astellas Inst For Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US10617557B2 (en) 2010-08-05 2020-04-14 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
US9492315B2 (en) 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
RS61601B1 (en) 2010-08-05 2021-04-29 Forsight Vision4 Inc Injector apparatus for drug delivery
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
EP2691127B1 (en) 2011-03-27 2021-01-13 Microsert Ltd Miniature implanted drug delivery devices and inserter systems for introducing such devices
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CN103917093B (en) 2011-06-14 2017-08-11 比卡姆药品公司 Opsin binding partner, composition and application method
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc Small molecule delivery with implantable therapeutic device
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2750660B1 (en) 2011-08-29 2016-10-12 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
EP4193907A1 (en) 2011-09-13 2023-06-14 Glaukos Corporation Intraocular physiological sensor
RS61758B1 (en) 2011-09-16 2021-05-31 Forsight Vision4 Inc Fluid exchange apparatus
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
EP2768307B1 (en) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
KR102054904B1 (en) 2011-11-14 2019-12-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Pharmaceutical preparations of human RPE cells and uses thereof
CA2862807A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
CA2862746A1 (en) 2011-12-01 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
MX362198B (en) 2011-12-23 2019-01-08 Depuy Synthes Products Llc Detection of human umbilical cord tissue-derived cells.
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
BR102012009316A2 (en) * 2012-04-20 2013-11-26 Univ Minas Gerais PROLONGED THAIDOMIDE RELEASE DEVICE AND USE IN EYE DISEASES CAUSING NEOVASCULARIZATION
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
MX351261B (en) 2012-06-01 2017-10-06 Surmodics Inc Apparatus and method for coating balloon catheters.
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
EP3228286A1 (en) 2012-09-17 2017-10-11 Novartis AG Expanding ocular impant devices
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2014078288A1 (en) 2012-11-14 2014-05-22 Transcend Medical, Inc. Flow promoting ocular implant
MX366404B (en) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods.
US20140234389A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
BR112015022208A8 (en) 2013-03-13 2018-01-23 Genzyme Corp fusion proteins comprising pdgf and vegf binding moieties, and methods of using it
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
CA2907681C (en) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US10098836B2 (en) 2013-05-02 2018-10-16 Retina Foundation Of The Southwest Method for forming a molded two-layer ocular implant
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
WO2015009534A2 (en) 2013-07-16 2015-01-22 Allergan, Inc. Hcn inhibitors affecting ganglion cell function and visual function
WO2015009533A1 (en) 2013-07-16 2015-01-22 Allergan, Inc. Gabaa receptor antagonists affecting ganglion cell function and visual function
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
US20170051290A1 (en) 2014-05-01 2017-02-23 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3157945A4 (en) 2014-06-20 2017-11-22 F. Hoffmann-La Roche AG Chagasin-based scaffold compositions, methods, and uses
RU2695563C2 (en) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Method and device for eye implant delivery
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN106573133B (en) 2014-08-19 2020-03-03 加利福尼亚大学董事会 Implants for localized drug delivery and methods of use thereof
EP3193829B1 (en) * 2014-09-19 2021-12-08 Oxular Limited Ophthalmic drug compositions
JP7037360B2 (en) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド Expandable drug delivery device
CN105769430B (en) * 2014-12-26 2018-09-28 易浦润（上海）生物技术有限公司 A kind of Punctual plugs carrying medicine
WO2016115369A1 (en) 2015-01-14 2016-07-21 Northwestern University Compositions, systems and methods for patient specific ophthalmic device
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP4349363A2 (en) 2015-10-07 2024-04-10 Apellis Pharmaceuticals, Inc. Dosing regimens
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
PT109154B (en) * 2016-02-12 2019-11-05 Univ De Coimbra NON-INVASIVE EYE INSERT TECHNOLOGY FOR CONTROLLED DRUG RELEASE
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
MX2018012021A (en) 2016-04-05 2019-01-24 Forsight Vision4 Inc Implantable ocular drug delivery devices.
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
EP3452013B1 (en) * 2016-05-02 2021-02-17 The Regents of The University of Michigan Coated implants for long-term controlled release of antibody therapeutics
SG11201811100RA (en) 2016-07-05 2019-01-30 Janssen Biotech Inc Treatment of retinal vascular disease using progenitor cells
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
AU2018249627A1 (en) 2017-04-07 2019-10-31 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
WO2019070917A1 (en) 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
EP3710008A4 (en) 2017-11-14 2021-08-25 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
BR112020010053A2 (en) 2017-11-21 2020-11-03 Forsight Vision4, Inc. fluid change device for expandable door release system and methods of using it
EP3787609A4 (en) * 2018-05-01 2022-01-05 Chibi, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
BR112020022087A2 (en) 2018-05-01 2021-02-02 Chibi, Inc. liquid depot for prolonged release of an active agent in the eye, joint, and, methods to treat an eye disease in an individual and to provide a protective coating for the eye.
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
CN114555017A (en) 2019-10-24 2022-05-27 D·E·拉波姆巴尔德 Eye-catching device, drug delivery system and housing
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
WO2023105417A1 (en) 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye
WO2023141251A1 (en) * 2022-01-24 2023-07-27 Celanese Eva Performance Polymers Llc Method for prohibiting and/or treating an eye condition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
WO1994018956A1 (en) * 1993-02-19 1994-09-01 Ahn Sam S Drug delivery system using hollow fibers
WO1999011244A1 (en) * 1997-08-28 1999-03-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
WO2000062760A1 (en) * 1999-04-19 2000-10-26 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297357A (en) 1962-08-31
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
SE390255B (en) 1974-02-18 1976-12-13 N G Y Torphammar RELEASE DEVICE PREFERRED FOR A SAFETY BELT IN A VEHICLE
US3921632A (en) 1974-08-16 1975-11-25 Frank M Bardani Implant device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4451254A (en) 1982-03-15 1984-05-29 Eli Lilly And Company Implant system
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5082655A (en) 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
DE3612212A1 (en) 1986-04-11 1987-10-15 Basf Ag METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5006342A (en) 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5004601A (en) 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
SE500489C2 (en) 1992-11-06 1994-07-04 Flaekt Ab Supply air device for ventilation air in ships
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
DE4403326C1 (en) 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraocular lens arrangement for astigmatism correction
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5693335A (en) 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
DE69816980T2 (en) * 1997-03-31 2004-07-22 Alza Corp., Palo Alto IMPLANTABLE DIFFUSION DELIVERY SYSTEM

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
WO1994018956A1 (en) * 1993-02-19 1994-09-01 Ahn Sam S Drug delivery system using hollow fibers
WO1999011244A1 (en) * 1997-08-28 1999-03-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
WO2000062760A1 (en) * 1999-04-19 2000-10-26 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968766B2 (en) 2004-04-30 2015-03-03 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8999397B2 (en) 2004-04-30 2015-04-07 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9233070B2 (en) 2004-04-30 2016-01-12 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants

Also Published As

Publication number Publication date
NO20013094L (en) 2001-08-22
KR20010099888A (en) 2001-11-09
EA200100694A1 (en) 2001-12-24
AU1218701A (en) 2001-05-08
BR0007454A (en) 2001-10-30
CA2355313C (en) 2007-03-06
CN1360497A (en) 2002-07-24
EP1143935A2 (en) 2001-10-17
JP4070460B2 (en) 2008-04-02
EP1143935A3 (en) 2002-09-18
CA2355313A1 (en) 2001-05-03
WO2001030323A2 (en) 2001-05-03
NO20013094D0 (en) 2001-06-21
US6331313B1 (en) 2001-12-18
JP2003512417A (en) 2003-04-02

Similar Documents

Publication Publication Date Title
WO2001030323A3 (en) Controlled-release biocompatible ocular drug delivery implant devices and methods
US4898733A (en) Layered, compression molded device for the sustained release of a beneficial agent
WO2005013936A3 (en) Manufacture of long term drug delivery devices with polyurethane based polymers
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
CA2230947A1 (en) Implantable controlled release device to deliver drugs directly to an internal portion of the body
WO2002049535A3 (en) Medicated polymer-coated stent assembly
CA2368335A1 (en) Inflatable device and method for treating glaucoma
CA2367209A1 (en) Stent security balloon/balloon cathether
CA2395077A1 (en) Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
CA2531833A1 (en) Poly-4-hydroxybutyrate matrices for sustained drug delivery
WO2004028570A3 (en) A method for treating severe tinnitus
WO2002047731A3 (en) Drug delivery compositions and coated medical devices
CA2305762A1 (en) Delayed total release gastrointestinal drug delivery system
MY133883A (en) Gastrointestinal drug delivery system
WO2001008717A9 (en) Controlled release implantable devices
CA2375714A1 (en) Delayed total release two pulse gastrointestinal drug delivery system
EP1473003A3 (en) Drug delivery device
WO2005115493A3 (en) Thermal treatment of an implantable medical device
CA2260750A1 (en) Methods for providing safe local anesthesia
ATE554806T1 (en) DEVICE FOR DELIVERING THERAPEUTIC AGENTS HAVING A SEPARATING PROTECTIVE LAYER
EP1125577A3 (en) Liquid drug delivery compositions
WO2005004945A3 (en) Thermal treatment of a drug eluting implantable medical device
WO2004000379A8 (en) Stent coatings with sustained drug release rate
WO2002011702A3 (en) Hydrogel-driven drug dosage form
WO2007011880A3 (en) Enhanced ocular neuroprotection/neurostimulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00803295.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/656/KOL

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2355313

Country of ref document: CA

Ref document number: 2355313

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000973704

Country of ref document: EP

Ref document number: 12187/01

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2001 532743

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020017007940

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200100694

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2000973704

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642